Cargando…

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

BACKGROUND: Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Haiyan, Ren, Peng, Chen, Yongzi, Lan, Lan, Yan, Zhuchen, Yang, Yinli, Wang, Bin, Wang, Cong, Li, Yanwei, Li, Ling, Zhang, Yu, Li, Yanyang, Wang, Zuolin, Pan, Zhanyu, Jiang, Zhansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979422/ https://www.ncbi.nlm.nih.gov/pubmed/36864384 http://dx.doi.org/10.1186/s12885-023-10637-4

Ejemplares similares

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
por: Jiang, Zhansheng, et al.
Publicado: (2021)

Baicalin reverses radioresistance in nasopharyngeal carcinoma by downregulating autophagy
por: Wang, Cong, et al.
Publicado: (2020)

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
por: Jiang, Zhansheng, et al.
Publicado: (2018)

Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells
por: Yanwei, Li, et al.
Publicado: (2018)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report
por: Friemel, Juliane, et al.
Publicado: (2016)

Efficacy of Traditional Chinese Medicine in Treatment and Prophylaxis of Radiation-Induced Oral Mucositis in Patients Receiving Radiotherapy: A Randomized Controlled Trial
por: Wang, Cong, et al.
Publicado: (2017)

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study
por: Syahruddin, Elisna, et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis
por: Lan, Bo, et al.
Publicado: (2022)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas
por: Pessôa, Igor Andrade, et al.
Publicado: (2019)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
por: Wang, Youping, et al.
Publicado: (2023)

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort
por: Machado-Rugolo, J., et al.
Publicado: (2023)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
por: Hou, Helei, et al.
Publicado: (2019)

Synthetic lethality between TP53 and ENDOD1
por: Tang, Zizhi, et al.
Publicado: (2022)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis
por: Zheng, Chang, et al.
Publicado: (2020)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Expression of TP53, BCL-2, and VEGFA Genes in Esophagus Carcinoma and its Biological Significance
por: Wei, Wei, et al.
Publicado: (2015)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis
por: Lin, Xiao-Yi, et al.
Publicado: (2023)

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer
por: Li, Ming, et al.
Publicado: (2016)

TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study
por: Hao, Fang, et al.
Publicado: (2022)

晚期非小细胞肺癌EGFR-TP53共突变的研究进展
Publicado: (2022)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
por: Feng, Juan, et al.
Publicado: (2023)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kdj0o10ql8fqg50shdpsqf4d3